Subscribe
shutterstock_1380818900_svetlichniy_igor
svetlichniy_igor / Shutterstock.com
12 February 2020AmericasSarah Morgan

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team